Supplementary Materials

The PDF file includes:

  • Fig. S1. Consort diagram.
  • Fig. S2. Results of OGTT tests over the first 36 months in (A) teplizumab- and (B) placebo-treated participants.
  • Fig. S3. Average on-study HbA1c values and proinsulin:C-peptide ratios are not significantly different between the treatment groups.
  • Fig. S4. Relationship of average on-study C-peptide AUC with age.
  • Fig. S5. C-peptide values are similar between treatment groups at the time of diagnosis.
  • Fig. S6. Changes in the number of circulating T cells at month 3 and C-peptide AUC at month 6.
  • Table S1. ANCOVA model of on-study glucose AUC mean.
  • Table S2. ANCOVA model of on-study A1c AUC mean (ln-ln transform).
  • Table S3. ANCOVA model of on-study C-peptide AUC mean [ln(x + 1) transform].
  • Table S4. Comparison of C-peptide AUC means among teplizumab and placebo groups and matched islet autoantibody–negative relatives (nontransformed values).
  • Table S5. Effect of HLA genotype and ZnT8 positivity on average C-peptide AUC.
  • Table S6. ANCOVA analysis of C-peptide AUC slope over the first 6 months on study.
  • Table S7. T cell phenotype flow cytometry panel.
  • Table S8. Intracellular cytokine staining flow cytometry panel.
  • Legends for data file S1 to S8

[Download PDF]

Other Supplementary Material for this manuscript includes the following: